Regaflo 5mg Tablet
₨ 449
About this product
Overview
Regaflo 5mg Tablet contains Solifenacin Succinate as its active ingredient. Solifenacin Succinate belongs to a class of medications known as antimuscarinic agents. It is primarily prescribed for the treatment of symptoms associated with overactive bladder (OAB), such as urinary urgency, frequency, and urge incontinence. Solifenacin works by blocking the action of certain receptors in the bladder, which helps to relax bladder muscles and improve control over urination.
Uses
- Overactive Bladder (OAB): Regaflo 5mg Tablet is indicated for the management of symptoms related to overactive bladder, including urinary urgency, frequency, and urge incontinence. By reducing bladder muscle contractions, Solifenacin Succinate helps to alleviate these symptoms and improve bladder control.
Side Effects
While Regaflo 5mg Tablet is generally well-tolerated, it may cause side effects in some individuals. Common side effects associated with Solifenacin Succinate include:
- Dry Mouth: Dry mouth is a common side effect of antimuscarinic medications like Solifenacin. Drinking water frequently, using sugar-free candies or gum, and practicing good oral hygiene can help alleviate this symptom.
- Constipation: Some patients may experience constipation while taking Regaflo 5mg Tablet. Consuming a diet rich in fiber, staying hydrated, and engaging in regular physical activity can help prevent or alleviate constipation.
- Blurred Vision: Blurred vision may occur in some individuals, especially at the beginning of treatment. Patients should avoid activities that require clear vision, such as driving, until vision clears up.
- Urinary Retention: In rare cases, Solifenacin Succinate may cause urinary retention, which is the inability to completely empty the bladder. Patients experiencing difficulty urinating should seek medical attention promptly.
Precautions
- Allergies: Patients with known allergies to Solifenacin Succinate or any components of the tablet should avoid using Regaflo 5mg Tablet.
- Liver or Kidney Impairment: Individuals with liver or kidney impairment should use Regaflo 5mg Tablet with caution, as dosage adjustments may be necessary to prevent adverse effects.
- Glaucoma: Patients with a history of narrow-angle glaucoma should use Solifenacin Succinate cautiously, as antimuscarinic medications can exacerbate this condition.
- Pregnancy and Breastfeeding: The safety of Regaflo 5mg Tablet during pregnancy and breastfeeding has not been established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.
This information is for general awareness only. It does not replace advice from your doctor or pharmacist. Always read the leaflet and follow the directions you were given.
Substitutes for Regaflo 5mg Tablet
These medicines contain the same salt as Regaflo 5mg Tablet (Solifenacin Succinate 5mg), so they are common substitutes. Compare their prices, and change brands only after checking with your doctor or pharmacist.
| Medicine | Manufacturer | Pack | Price |
|---|---|---|---|
| Ufi 5mg Tablet | Pharmevo | 10 tablets | Rs 410 |
| Uricontrol 5mg Tablet | Aspin Pharma | 1x10'S | Rs 448.52 |
| Vesibar 5mg Tablet | Barrett Hodgson | 10 tablets | Rs 451 |
| Urgesin 5 mg Tablet | AGP Pharmacuticals | 10s | Rs 492.28 |
| Solif 5mg Tablet | Genix Pharma | 10s | Rs 558.40 |
| Solfy 5mg Tablet | Sami Pharma | 10s | Rs 655 |
| Vezitic 5mg Tablet | CCL Pharmaceuticals | 10s | Rs 816.20 |
| Solifen 5mg Tablets | Getz Pharma | 10 Tablets In a Pack | Rs 820 |
Other strengths of Solifenacin Succinate
| Medicine | Manufacturer | Strength | Price |
|---|---|---|---|
| Ufi 10mg Tablet | Pharmevo | 10mg | Rs 600 |
| Regaflo 10mg Tablet | Ferozsons Laboratories | 10mg | Rs 683 |
| Uricontrol 10mg Tablet | Aspin Pharma | 10mg | Rs 765.77 |
| Urgesin 10 mg Tablet | AGP Pharmacuticals | 10mg | Rs 853.28 |
See all brands and prices on our Solifenacin Succinate page.
Customer reviews
You must be logged in to post a review.



Reviews
Clear filtersThere are no reviews yet.